The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Slides:

Advertisements

Similar presentations

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Advertisements

Pinja Ilmarinen, PhD, Leena E

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma Geneviève Racine, Roberto Castano, MD, PhD, André Cartier, MD, Catherine.

Advances in Diagnosing Peanut Allergy

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence Laurent Laforest, MD, PhD, Manon Belhassen, MSc, Gilles Devouassoux,

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Effect of montelukast for treatment of asthma in cigarette smokers

Shyam Joshi, MD, David A. Khan, MD

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

Desensitization to Chemotherapeutic Agents

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Felix Ratjen, Paul Koker, David E

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Clinical Management of Food Allergy

Badrul A. Chowdhury, MD, PhD

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers Robert A. Wise,

Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations Kazuto Matsunaga, MD, PhD, Tsunahiko Hirano, MD, PhD,

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study Rachel A. Charlton, PhD, Julia M. Snowball,

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena.

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Validation of the Pregnancy Asthma Control Test

Advances in Diagnosing Peanut Allergy

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Severe Asthma: An Expanding and Mounting Clinical Challenge

Nonadherence to Asthma Treatment: Getting Unstuck

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Necdet B. Gunsoy, PhD, Sarah M. Cockle, PhD, Steven W

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Change in Asthma Control Over Time: Predictors and Outcomes

Phillip Lieberman, MD, Michael Tankersley, MD

Effects of Mometasone, Fluticasone, and Montelukast on Bone Mineral Density in Adults with Asthma Jorge Maspero, MD, Vibeke Backer, DMSci, MD, Ruji Yao,

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

The Management of Eosinophilic Esophagitis

Phillip Lieberman, MD, David Golden, MD

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Mapping the Asthma Care Process: Implications for Research and Practice Alexandra Lelia Dima, PhD, Marijn de Bruin, PhD, Eric Van Ganse, MD, PhD, FRCP

Pinja Ilmarinen, PhD, Leena E

Sharon Seth, MD, David A. Khan, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

The Journal of Allergy and Clinical Immunology: In Practice

Eckard Hamelmann, MD, Eric D

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network.

What Is Chronic Cough? Terminology

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Daniel Menzies, MBChB, Arun Nair, MBBS, Karen T

News & Notes Journal of Allergy and Clinical Immunology

Presentation transcript:

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro, MD, David M.G. Halpin, FRCP, Roland Buhl, MD, PhD, Michael Engel, MD, Valentina B. Zubek, PhD, Zuzana Blahova, PharmDr, Petra Moroni-Zentgraf, MD, Emilio Pizzichini, DD, PhD The Journal of Allergy and Clinical Immunology: In Practice Volume 4, Issue 1, Pages 104-113.e2 (January 2016) DOI: 10.1016/j.jaip.2015.08.017 Copyright © 2015 The Authors Terms and Conditions

Figure 1 Patient disposition. AE, adverse event. The Journal of Allergy and Clinical Immunology: In Practice 2016 4, 104-113.e2DOI: (10.1016/j.jaip.2015.08.017) Copyright © 2015 The Authors Terms and Conditions

Figure 2 Adjusted mean peak FEV1(0-3h) response over the 12-week study period. *P < .05; **P < .001. Response defined as a difference from the baseline value at randomization. Error bars are ± standard error. Baseline mean (standard deviation) FEV1, mL, at visit 2: 2420 (711). Adjusted for treatment, center, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. FEV1, forced expiratory volume in 1 second; peak FEV1(0-3h), peak forced expiratory volume in 1 second within 3 hours of dosing. The Journal of Allergy and Clinical Immunology: In Practice 2016 4, 104-113.e2DOI: (10.1016/j.jaip.2015.08.017) Copyright © 2015 The Authors Terms and Conditions

Figure 3 Adjusted mean weekly morning PEF (A) and adjusted mean weekly evening PEF (pre-bronchodilator) (B). P < .05 vs placebo for both tiotropium doses at all time points. Response defined as a difference from the baseline value at randomization. Error bars are ± standard error. Baseline mean (standard deviation) PEF, L/min, at visit 2: morning, 355.8 (114.5); evening, 369.8 (115.0). PEF, peak expiratory flow. The Journal of Allergy and Clinical Immunology: In Practice 2016 4, 104-113.e2DOI: (10.1016/j.jaip.2015.08.017) Copyright © 2015 The Authors Terms and Conditions